1236. Update on the In Vitro Activity of Ceftaroline against Staphylococcus aureus from United States (US) Medical Centers Stratified by Infection Type (2018-2020)

BACKGROUND: Ceftaroline was initially approved by the US FDA in 2010 to treat skin and skin structure infection (SSSI) and community-acquired bacterial pneumonia (CABP). FDA approval was extended in 2015 to treat patients with SSSI and CABP who developed bacteremia. Moreover, ceftaroline has also be...

Descripción completa

Detalles Bibliográficos
Autores principales: Sader, Helio S, Castanheira, Mariana, Duncan, Leonard R, Mendes, Rodrigo E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644559/
http://dx.doi.org/10.1093/ofid/ofab466.1428

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644559/
http://dx.doi.org/10.1093/ofid/ofab466.1428

Ejemplares similares